Marc de Somer MD ScD MPH MSc MBA

Marc de Somer MD ScD MPH MSc MBA has a diverse work experience in the medical and pharmaceutical industry. Marc is currently the Chief Medical Officer at NeuroTrauma Sciences, LLC since April 2023. Prior to this role, they worked as a Chief Medical Officer Consultant for multiple companies from November 2022 to May 2023.

From March 2020 to November 2022, Marc served as the SVP Clinical Development and Safety at Relmada Therapeutics, Inc. Marc also held the position of Chief Medical Officer at Prilenia from June 2019 to March 2020 and at CMO-level Clinical-Medical-Quant Consulting from December 2018 to March 2020.

Before that, Marc was the VP of Clinical Development at Voyager Therapeutics, Inc. from December 2017 to December 2018. Marc had a significant tenure at PPD, where they worked as the VP Global Product Development Neuroscience from September 2014 to July 2017, providing strategic advice and developing innovative clinical trial methodologies.

From March 2010 to July 2014, Marc held the role of Vice President of Clinical Development & Medical Affairs at Alkermes. Marc served as a Strategic Advisor to the CEO at Adagio Pharmaceuticals merged with Cynapsus Therapeutics from November 2008 to 2010. Earlier in their career, they were the Chief Medical Officer & Executive Vice President of R&D at Cervelo Pharmaceuticals, Inc.

Marc's extensive experience in leadership and clinical development roles demonstrates their expertise in enhancing clinical research and medical affairs, as well as their ability to provide strategic advice for value creation and accelerated clinical R&D with reduced risk, time, and cost.

Marc de Somer MD ScD MPH MSc MBA has an extensive education history. Marc obtained their medical degree (MD) from Vrije Universiteit Brussel in 1980. Following that, they pursued a specialization in Tropical Medicine and Infectious Diseases, earning a Doctor of Science (ScD) from Prins Leopold Instituut voor Tropische Geneeskunde from 1980 to 1982.

In 1977, they enrolled at Université libre de Bruxelles and completed a Master of Public Health (MPH) degree, focusing on Public Health, Epidemiology, and Biostatistics, which they completed in 1982. Continuing their interest in biostatistics, they participated in a Joint Biostatistics MSc program conducted by Harvard School of Public Health, Imperial College, and Leuven University from 1988 to 1990.

To further their knowledge in epidemiology, they attended Tufts University School of Medicine from 1984 to 1985, where they pursued postgraduate studies in Epidemiology. Moving on to the field of pharmaceutical medicine, they studied at the University of Basel from 1992 to 1993, obtaining a Master of Science (MSc) degree in Swiss FMH Pharmaceutical Medicine Specialty.

Lastly, in 1996, they attended Columbia Business School to broaden their expertise in business administration, earning a Master of Business Administration (MBA) degree in 1998.